Grace Therapeutics, Inc. 8-K Filing: Upcoming Insights for Investors on Feb 13, 2025

Here's a breakdown of the key information extracted from the provided financial report section:

Filing Type:

Form 8-K

Company Information:

Name: Grace Therapeutics, Inc.
State of Incorporation: Delaware (DE)
CIK Number: 0001444192
Address: 103 Carnegie Center, Suite 300, Princeton, NJ 08540
Phone Number: 609-322-1602

Securities Information:

Common Stock:
- Par Value: $0.0001 per share
- Ticker Symbol: GRCE
- Exchange: NASDAQ

Reporting Period:

Date of Report: February 13, 2025
Period Covered: Single day, February 13, 2025

SEC Reference:

Schema Reference: grce-20250213.xsd

Insights:

The report is a timely filing under Form 8-K, which typically indicates that the company is reporting unscheduled material events or corporate changes that are important to shareholders.
The company is publicly traded on NASDAQ under the ticker GRCE, which provides an insight into its accessibility and potential market interest.
The date of the report being in the future (February 13, 2025) suggests that the information may pertain to a planned event or announcement expected on that date, which could be significant for investors and analysts tracking the company’s performance or strategic moves.

Overall, this information is crucial for stakeholders to understand the company's current reporting obligations, stock details, and the context of the report.